Kestra Medical Technologies, Ltd.

NASDAQ:KMTS

Medical - Instruments & Supplies

Healthcare
$28.29 -0.37%

-$0.07 today

Market cap
$1.69B
Beta
0.83
P/E (TTM)
-6.9
EPS (TTM)
-$2.74
52W Low $13.25High $30.00

Volume 0.44M

Average 0.33M

KMTS EBITDA Margin

EBITDA as a percentage of revenue.

Kestra Medical Technologies, Ltd.NASDAQ: KMTS

EBITDA Margin · Q3 FY2026 · quarter ended Jan 2026

EBITDA Margin narrows to -123.2%

EBITDA Margin was -123.2% in Q3 FY2026, down 3.5 pp from a year earlier. On a trailing-twelve-month basis it was -152.9%, down 23.0 pp year over year.

Context

  • EBITDA Margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -129.4% for the fiscal year ending Apr 2026, up from -163.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJan 2026
-123.2%+3.0 pp QoQ
Last fiscal yearApr 2025
-163.8%+110.5 pp YoY
LTMJan 2026
-152.9%-23.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.5 pp+160.4 pp+163.9 pp
1 year+110.5 pp+34.4 pp-76.1 pp
3 years—+121.7 pp—
5 years+167.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-163.8%
Year-over-year change
+110.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How KMTS compares with its peers on the latest reported figures

  • KMTS's LTM Jan 2026 EBITDA Margin of -152.9% is the lowest of the 3 companies compared; the peer median is -39.5%.
  • Its year-over-year change of -23.0 pp is the lowest of 3, against a peer median of +4.8 pp.
KMTS Competitors Peer median
EBITDA Margin for KMTS and competitors
Company Period LTM level YoY 3-year change
IRTCiRhythm Technologies, Inc.LTM Sep 2026-1.2% +0.4 pp+21.9 pp
CVRXCVRx, Inc.LTM Mar 2026-77.8% +9.1 pp+98.8 pp
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026-152.9% -23.0 pp—
Peer median (excluding KMTS) -39.5%+4.8 pp+60.4 pp

Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2020
Apr 2020
FY2021
Apr 2021
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue007.63M27.81M59.82M
Cost of Revenue0018.28M27.45M35.61M
Gross Profit00(10.65M)362K24.21M
Gross Margin——-139.6%1.3%40.5%
Research & Development22.8M18.81M15.76M15.49M15.65M
Selling, General & Admin6.52M13.9M54.01M69.94M114.94M
Operating Expenses29.32M32.71M69.77M85.43M130.59M
Depreciation & Amortization478K420K4.86M11.56M7.97M
EBITDA(28.84M)(32.33M)(73.74M)(76.31M)(97.98M)
EBITDA Margin——-966.4%-274.3%-163.8%
Operating Income(29.32M)(32.71M)(80.42M)(85.06M)(106.38M)
Operating Margin——-1054.0%-305.8%-177.8%
Interest Income00003.2M
Interest Expense01.17M5.63M6.23M7.73M
Other Income / Expenses0(1.21M)(3.8M)(9.03M)(7.3M)
Income Before Tax(29.32M)(33.91M)(84.22M)(94.1M)(113.68M)
Pre-Tax Margin——-1103.8%-338.3%-190.1%
Income Tax Expense148K187K15K24K135K
Net Income(29.47M)(34.1M)(84.24M)(94.12M)(113.81M)
Net Margin——-1104.0%-338.4%-190.3%
EPS (Basic)(0.59)(0.69)(1.75)(2.04)(5.13)
EPS (Diluted)(0.59)(0.69)(1.75)(2.04)(5.13)
Weighted Avg Shares49.53M49.53M49.53M49.53M49.53M
Weighted Avg Shares (Diluted)49.53M49.53M49.53M49.53M49.53M

Kestra Medical Technologies, Ltd.

NASDAQ:KMTS

Intrinsic Alpha fair value

Locked

Current Price

$28.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.